Curcumin-dependent phenotypic transformation of microglia mediates resistance to pseudorabies-induced encephalitis

Luqiu Feng, Guodong Luo, Yuhang Li, Chen Zhang, Yuxuan Liu, Yanqing Liu, Hongyue Chen, Daoling He, Yan Zhu, Ling GanVeterinary 2023 · DOI

Abstract

Pseudorabies virus (PRV) causes viral encephalitis, a devastating disease with high mortality worldwide. Curcumin (CUR) can reduce inflammatory damage by altering the phenotype of microglia; however, whether and how these changes mediate resistance to PRV-induced encephalitis is still unclear. In this study, BV2 cells were infected with PRV and treated with CUR. The results indicated that CUR promoted the polarization of PRV-infected BV2 cells from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype and reversed PRV-induced mitochondrial dysfunction. RNA sequencing and bioinformatics analysis predicted that this phenotypic shift was driven by changes in energy metabolism. Specifically, CUR inhibited the increase in AMPK phosphorylation and glycolysis while restoring oxidative phosphorylation. Furthermore, CUR prevented mortality and clinical symptoms in vivo. This study demonstrates that CUR protects against PRV-induced viral encephalitis by switching the microglial phenotype via the AMPK/NF-κB p65-energy metabolism-related pathway.

What Problem Does This Paper Address?

Pseudorabies virus (PRV) is a highly contagious herpesvirus that primarily affects livestock but has recently emerged as a threat to human health, causing acute, often fatal encephalitis. When PRV invades the central nervous system (CNS), it triggers microglia—the brain's resident immune cells—to enter an aggressive "M1" phenotype.

While M1 microglia aim to kill pathogens by releasing inflammatory cytokines and reactive oxygen species (ROS), an overactive response causes collateral damage to healthy neurons. The challenge is finding a way to "switch" these cells into an "M2" phenotype, which focuses on resolving inflammation and repairing tissue. While Curcumin is known for its anti-inflammatory properties, the specific molecular mechanisms it uses to mediate resistance to viral encephalitis remained a mystery until now.

Methods

The researchers employed a multi-tiered approach combining cell cultures and live animal models:

  • Cell Models: They used BV2 cells (a microglial cell line) and PC-12 cells (neuron-like cells), validating findings with primary microglial cultures from mice.
  • Viral Infection: Cells and rats were infected with PRV to simulate encephalitis. The study established the infection model by observing viral replication across various titers.
Microscopy showing PRV infection levels across different viral titers (TCID50).
  • Metabolic & Phenotypic Analysis: To track the M1-to-M2 shift, the team used flow cytometry and RNA sequencing (RNA-seq) to identify gene expression changes.
  • Mechanistic Probing: They used Western blotting to monitor protein signaling and Seahorse assays to measure cellular respiration. To prove the role of the AMPK pathway, they used chemical inhibitors and siRNA.
  • In Vivo Testing: Sprague-Dawley rats were treated with varying doses of Curcumin to observe clinical outcomes like survival and brain pathology.

Key Insights and Ideas

  • The Metabolic Switch: The study links immune phenotype to energy metabolism. M1 microglia rely heavily on aerobic glycolysis, while M2 microglia favor oxidative phosphorylation (OXPHOS). Curcumin restores mitochondrial function, reversing the PRV-induced drop in mitochondrial membrane potential.
  • The AMPK/NF-κB Axis: The study identifies AMPK as the master regulator. Curcumin activates AMPK, which in turn inhibits the NF-κB p65 pathway. This dual action shuts down pro-inflammatory signals while shifting the cell's energy production toward stable M2-associated pathways.
  • Oxidative Stress Mitigation: A critical component of PRV damage is the induction of reactive oxygen species (ROS), which increases significantly over time following infection.
Intracellular ROS levels increase significantly over 24 hours following PRV infection.
  • Neuroprotection by Proxy: Interestingly, Curcumin's protective effect on neurons was indirect. Neurons treated with the secretions of M1 microglia died, but those treated with secretions from Curcumin-treated (M2) microglia survived, proving that Curcumin saves neurons by managing their environment.

Key Results

  • Survival Rates: In the rat model, PRV infection resulted in a 70% survival rate. High-dose Curcumin treatment boosted survival to 90-100%.
  • Clinical Symptoms: Curcumin significantly reduced fever, prevented weight loss, and calmed the nervous system excitation typically seen in PRV-infected rats.
  • Pathology: Brain tissue from treated rats showed a marked reduction in vascular cuffing (inflammation around blood vessels) and congestion compared to the untreated PRV group.
  • Cytokine Regulation: Curcumin treatment led to a significant decrease in pro-inflammatory markers (TNF-α, IL-6, NO) and a significant increase in anti-inflammatory markers (IL-4, IL-10).

Limitations and Future Work

While the results are promising, several hurdles remain:

  • Cell Line Limitations: Much of the mechanistic work was done in BV2 cells. While validated with primary cells, the complex environment of a human brain is much harder to replicate.
  • Bioavailability: Curcumin is notoriously difficult for the body to absorb. The study used intraperitoneal injections; translating this to an effective oral supplement for humans remains a significant hurdle.
  • Viral Specificity: The study focuses on PRV. It remains to be seen if this metabolic reprogramming strategy is equally effective against other neurotropic viruses like Herpes Simplex or Rabies.

Future research will likely focus on developing Curcumin derivatives with better brain penetration and testing these metabolic interventions in more advanced "brain-on-a-chip" models.

Summary updated

Abstract

Pseudorabies virus (PRV) causes viral encephalitis, a devastating disease with high mortality worldwide. Curcumin (CUR) can reduce inflammatory damage by altering the phenotype of microglia; however, whether and how these changes mediate resistance to PRV-induced encephalitis is still unclear. In this study, BV2 cells were infected with/without PRV for 24 h and further treated with/without CUR for 24 h. The results indicated that CUR promoted the polarization of PRV-infected BV2 cells from the M1 phenotype to the M2 phenotype and reversed PRV-induced mitochondrial dysfunction. Furthermore, M1 BV2 cell secretions induced signalling pathways leading to apoptosis in PC-12 neuronal cells, and this effect was abrogated by the secretions of M2 BV2 cells. RNA sequencing and bioinformatics analysis predicted that this phenotypic shift may be due to changes in energy metabolism. Furthermore, Western blot analysis showed that CUR inhibited the increase in AMP-activated protein kinase (AMPK) phosphorylation, glycolysis, and triacylglycerol synthesis and the reduction in oxidative phosphorylation induced by PRV infection. Moreover, the ATP levels in M2 BV2 cells were higher than those in M1 cells. Furthermore, CUR prevented the increase in mortality, elevated body temperature, slowed growth, nervous system excitation, brain tissue congestion, vascular cuffing, and other symptoms of PRV-induced encephalitis in vivo. Thus, this study demonstrated that CUR protected against PRV-induced viral encephalitis by switching the phenotype of BV2 cells, thereby protecting neurons from inflammatory injury, and this effect was mediated by improving mitochondrial function and the AMPK/NF-κB p65-energy metabolism-related pathway.
BibTeX
@inproceedings{feng2023curcumin,
  author = {Luqiu Feng and Guodong Luo and Yuhang Li and Chen Zhang and Yuxuan Liu and Yanqing Liu and Hongyue Chen and Daoling He and Yan Zhu and Ling Gan},
  title = {{Curcumin-dependent phenotypic transformation of microglia mediates resistance to pseudorabies-induced encephalitis}},
  booktitle = {Veterinary},
  year = {2023},
  doi = {10.1186/s13567-023-01149-x},
}
Figure